Biosynex 配当金

配当金基準チェック /06

Biosynex does not currently pay a dividend.

主要情報

配当利回り

10.7%

バイバック利回り

総株主利回り	10.7%
将来の配当利回り	n/a
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	€2.000
配当性向	0%

最近の配当金アップデート

Recent updates

決済の安定と成長

配当データの取得

安定した配当: Insufficient data to determine if 0DL's dividends per share have been stable in the past.

増加する配当: Insufficient data to determine if 0DL's dividend payments have been increasing.

配当利回り対市場

Biosynex 配当利回り対市場

0DL 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (0DL)	0%
市場下位25% (DE)	1.6%
市場トップ25% (DE)	4.8%
業界平均 (Medical Equipment)	2.0%
アナリスト予想 (0DL) (最長3年)	n/a

注目すべき配当: Unable to evaluate 0DL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

高配当: Unable to evaluate 0DL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

株主への利益配当

収益カバレッジ: 0DL is not paying a notable dividend for the German market.

株主配当金

キャッシュフローカバレッジ: Unable to calculate sustainability of dividends as 0DL has not reported any payouts.

Biosynex 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Upcoming dividend of €2.00 per share

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06